Search

Displaying results 2961 - 2970 of 8517 in total
  1. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. A monoclonal antibody combined with a toxic substance that is used treat certain types of acut...

  2. Drug

    Daleuton

    go.drugbank.com/drugs/DB00154
    InvestigationalNutraceutical

    A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.

  3. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    Available as either "Synthetic Conjugated Estrogens, A" containing 9 estrogen derivatives (available as Cenestin) or as "Synthetic Conjugated Estrogens, B" containing 10 estrogen derivatives (available … as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.

  4. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  5. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as

  6. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult

  7. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    growth factor (VEGF), basic fibroblast growth factor (bFGF), as well as other pro-angiogenic growth factors. … The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  8. Drug

    Synthetic Conjugated Estrogens, B

    go.drugbank.com/drugs/DB09318
    Approved

    Available as either "Synthetic Conjugated Estrogens, A" containing 9 estrogen derivatives (available as Cenestin) or as "Synthetic Conjugated Estrogens, B" containing 10 estrogen derivatives (available … as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.

  9. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … It is available commercially as the monoclonal antibody portion of the antibody-drug conjugate [brentuximab vedotin].

  10. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    Some studies suggest pipamperone was the first atypical antipsychotic. Interestingly, when [risperidone] was created, Janssen suggested it was a more potent version of pipamperone. … It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518].